The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating the efficacy of fruquintinib versus regorafenib and trifluridine/tipiracil in treating advanced metastatic colorectal cancer: A match-adjusted indirect comparison.
 
Shukui Qin
No Relationships to Disclose
 
Jin Li
No Relationships to Disclose
 
Ruihua Xu
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Jianmin Xu
No Relationships to Disclose
 
Yuxian Bai
No Relationships to Disclose
 
Lei Yang
No Relationships to Disclose
 
Yanhong Deng
No Relationships to Disclose
 
Zhendong Chen
No Relationships to Disclose
 
Haijun Zhong
No Relationships to Disclose
 
Hongming Pan
No Relationships to Disclose
 
Weijian Guo
No Relationships to Disclose
 
Yongqian Shu
No Relationships to Disclose
 
Ying Yuan
No Relationships to Disclose
 
Jianfeng Zhou
No Relationships to Disclose
 
Nong Xu
No Relationships to Disclose
 
Tianshu Liu
No Relationships to Disclose
 
Dong Ma
No Relationships to Disclose
 
Changping Wu
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose